The global AI in Neurology Market is experiencing rapid expansion as healthcare providers increasingly adopt artificial intelligence to improve neurological diagnosis, disease monitoring, clinical decision-making, and treatment planning. The growing prevalence of neurological disorders, rising demand for early diagnosis, advances in neuroimaging, and increasing integration of machine learning into healthcare workflows are creating strong opportunities for AI technology providers. AI-powered solutions are helping clinicians analyze complex neurological data more efficiently while supporting faster and more personalized patient care. 

Market Overview & Growth Trajectory

Artificial intelligence is becoming increasingly important in neurology because neurological disorders often require the analysis of large and complex datasets, including MRI and CT scans, EEG signals, clinical records, and other patient information. AI and machine learning technologies can identify patterns within these datasets, support automated image interpretation, and assist healthcare professionals in detecting neurological abnormalities.

According to Grand View Research, the market is entering a high-growth phase as healthcare organizations increase investments in AI-enabled diagnostic and monitoring technologies.

• Market Size (2025): USD 760.0 million 

• Estimated Market Size (2026): USD 937.2 million 

• Projected Market Size (2033): USD 4,451.5 million 

• CAGR (2026–2033): 24.9% 

• Dominant Region: North America 

• North America Revenue Share (2025): 52.5%

Download a free sample copy of the AI In Neurology Market report to understand detailed coverage and inclusions in the final report

Key Market Segments

• By Component: The software segment dominated the market with a 58.0% revenue share in 2025. AI-powered software platforms are increasingly being used for neurological diagnosis, neuroimaging analysis, predictive analytics, and clinical decision support. The AI-enabled devices segment is expected to be the fastest-growing component during the forecast period, supported by increasing demand for real-time monitoring and point-of-care diagnostics. 

• By Application: Neuroimaging & diagnostics held the largest share at 36.0% in 2025. AI-powered tools integrated with MRI and CT technologies can help identify abnormalities associated with stroke, brain tumors, and neurodegenerative disorders. Meanwhile, disease progression monitoring is expected to grow at the fastest CAGR as healthcare providers increasingly use AI for continuous monitoring and personalized treatment strategies. 

• By Neurological Condition: The stroke segment accounted for the largest revenue share of 26.8% in 2025. Rapid diagnosis and treatment planning are major factors supporting the use of AI in stroke care. Alzheimer’s disease & dementia is expected to be the fastest-growing segment, driven by the rising aging population and increasing demand for early detection and disease progression assessment. By End Use: Hospitals & clinics represented the largest end-use segment, accounting for 57.7% of revenue share in 2025. AI tools are increasingly deployed in clinical environments to improve diagnostic accuracy and process large volumes of patient information. Neurology centers are expected to experience the fastest growth through 2033. 

Major Market Drivers

Rising Prevalence of Neurological Disorders

The increasing burden of neurological diseases is one of the strongest factors supporting AI adoption. Conditions such as stroke, Alzheimer’s disease, Parkinson’s disease, epilepsy, multiple sclerosis, and traumatic brain injury require timely diagnosis and long-term monitoring. AI can assist clinicians in identifying disease-related patterns and extracting meaningful insights from complex neurological datasets. 

Growing Need for Early Diagnosis

Early diagnosis is particularly important in neurological care because several conditions can develop gradually before symptoms become clearly visible. AI-based neuroimaging and diagnostic platforms can identify subtle abnormalities and support earlier clinical intervention.

The increasing use of AI with MRI, CT, and EEG systems is improving the ability of healthcare professionals to analyze neurological information. Grand View Research highlights the growing importance of AI-powered tools for early detection, disease monitoring, and personalized treatment. 

Government and Regulatory Support

Government initiatives, digital-health investments, and evolving regulatory frameworks are also supporting market development. Regulatory agencies are increasingly evaluating and clearing AI-based medical devices and software, encouraging healthcare organizations to integrate these technologies into clinical workflows. 

Challenges & Market Inhibitors

Despite strong growth prospects, the AI in neurology market faces several challenges. Clinical adoption requires AI systems to demonstrate reliability, accuracy, and compatibility with existing healthcare infrastructure. Data quality and interoperability can also affect the performance of AI models.

Regulatory requirements represent another important consideration. AI-based medical technologies must undergo appropriate clinical validation and comply with evolving requirements related to safety, data quality, cybersecurity, and lifecycle management.

Healthcare organizations also need skilled professionals who can effectively integrate AI outputs into clinical decision-making. These factors can influence the pace of adoption, particularly in healthcare systems with limited technological infrastructure. 

Looking for more specific insights? Customize this report to suite your business needs

Regional Growth Outlook

North America dominated the AI in neurology market with a 52.5% revenue share in 2025. Strong technological capabilities, advanced healthcare infrastructure, high adoption of AI and machine learning, and emphasis on early neurological diagnosis are supporting regional leadership. The U.S. held the largest country-level market share in 2025. 

Asia Pacific is the fastest-growing regional market over the forecast period. Increasing neurological disease prevalence, expanding digital healthcare infrastructure, and rising adoption of AI-powered diagnostic technologies in countries such as China, India, and Japan are contributing to regional expansion. 

Competitive Landscape

The competitive environment includes AI developers, medical technology companies, neuroimaging providers, and specialized neurological technology companies. Key companies profiled by Grand View Research include:

• Cortechs.ai

• Viz.ai

• RapidAI (trademarks of iSchemaView, Inc)

• Aidoc

• Brainomix

• Avicenna.AI

• Natus

• Hyperfine

• PERSYST DEVELOPMENT LLC

• Ceribell, Inc.

• Empatica Inc.

• GE Healthcare

• Koninklijke Philips N.V.

• Siemens Healthiness

Companies are focusing on product launches, regulatory clearances, strategic partnerships, and technological development to strengthen their positions. Recent developments include AI-powered stroke detection, EEG analysis, portable brain MRI, neuroimaging analytics, and other neurological applications.